A company developing messenger RNA therapeutics on demand from single-use biochips is raising $60 million in its second venture funding round. . . . → Read More: Chip-Based RNA Biotech Raises $60M in Venture Funds
|
|||||
|
       
  |
A company creating a blood test to screen for multiple types of cancer is being acquired by genomics analytics company Illumina for $8 billion in cash and stock. . . . → Read More: Cancer Screening Analytics Company Acquired in $8B Deal 
A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer. . . . → Read More: Mental Health Drug Company Raises $127.5M in IPO 
A company creating cancer therapies with individualized engineered T-cells is raising $110 million in its first venture funding round. . . . → Read More: Precision Cancer Therapy Start-Up Gains $110M in Early Funds 
Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion. . . . → Read More: Gilead Acquires Cancer Therapy Biotech for $21B 
A new enterprise formed to discover human therapeutic antibodies is partnering with a synthetic biology company to discover Covid-19 antibody treatments. . . . → Read More: Antibody Discovery Company Forms, Partners on Covid-19 
A Belgian company creating virtual reality systems for sedation in surgery and invasive procedures is raising €10 million in its first venture funding round. . . . → Read More: Digital Sedation Company Raises $11.8M in Early Funds  One comment - (Comments are closed)  Finance, New products  behavioral science, biomedical, clinical trials, engineering, entrepreneurs, equity, Europe, investment, life sciences, medical device, physical sciences, software, venture capital 
Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion. . . . → Read More: Food Allergy Biotech Acquired for $2.6B One comment - (Comments are closed) Finance biomedical, biotechnology, equity, Europe, FDA, investment, life sciences, merger, pharmaceuticals Looking back to May shows that NBI has largely settled in to the 4,000 to 4,500 range, without volatile swings in either direction. . . . → Read More: Infographic – Biotech Index Cruising in High Range 
A developer of small-molecule therapies for autoimmune diseases, including multiple sclerosis, and other immune disorders is being acquired by Sanofi. . . . → Read More: Sanofi Acquires Immune Disease Biotech in $3.7B Deal One comment - (Comments are closed) Finance biomedical, biotechnology, clinical trials, equity, Europe, investment, licensing, life sciences, merger, pharmaceuticals |
||||
|
Copyright © 2020 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||